GoodRx (GDRX) Financials

$3.74 -0.08 (-2.09%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$3.74 -0.01 (-0.13%)

As of 05/23/2025 06:16 PM Eastern

Annual Income Statements for GoodRx

This table shows GoodRx's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Net Income / (Loss) Attributable to Common Shareholders	16	-8.87	-33	-25	-294	66	14
Consolidated Net Income / (Loss)	16	-8.87	-33	-25	-294	76	44
Net Income / (Loss) Continuing Operations	16	-8.87	-33	-25	-294	76	44
Total Pre-Tax Income	31	-56	-23	-10	-303	83	52
Total Operating Income	66	-27	1.74	13	-276	140	77
Total Gross Profit	744	683	701	699	521	374	243
Total Revenue	792	750	767	745	551	388	250
Operating Revenue	792	750	767	745	551	388	250
Total Cost of Revenue	48	67	65	47	30	14	6.04
Operating Cost of Revenue	48	67	65	47	30	14	6.04
Total Operating Expenses	678	710	700	685	797	235	166
Selling, General & Admin Expense	118	126	145	155	461	15	8.36
Marketing Expense	367	341	358	370	255	177	104
Research & Development Expense	124	136	143	126	62	29	44
Depreciation Expense	70	108	54	35	18	14	9.81
Total Other Income / (Expense), net	-34	-29	-25	-24	-28	-57	-25
Interest Expense	55	57	34	24	28	54	25
Interest & Investment Income	23	32	9.27	0.06	0.16	0.72	0.15
Other Income / (Expense), net	-2.66	-4.01	0.00	0.00	-0.02	-2.97	-0.01
Income Tax Expense	15	-47	9.60	15	-9.83	17	8.56
Basic Earnings per Share	$0.04	($0.02)	($0.08)	($0.06)	($1.07)	$0.19	$0.12
Weighted Average Basic Shares Outstanding	385.74M	410.32M	412.86M	409.98M	274.70M	226.61M	111.84M
Diluted Earnings per Share	$0.04	($0.02)	($0.08)	($0.06)	($1.07)	$0.18	$0.12
Weighted Average Diluted Shares Outstanding	392.17M	410.32M	412.86M	409.98M	274.70M	231.21M	118.34M
Weighted Average Basic & Diluted Shares Outstanding	383.61M	395.00M	397.57M	400.85M	392.13M	-	-

This table shows GoodRx's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	11	6.74	3.97	6.69	-1.01	-26	-38	59	-3.29	-1.97	-42
Consolidated Net Income / (Loss)	11	6.74	3.97	6.69	-1.01	-26	-38	59	-3.29	-1.97	-42
Net Income / (Loss) Continuing Operations	11	6.74	3.97	6.69	-1.01	-26	-38	59	-3.29	-1.97	-42
Total Pre-Tax Income	17	11	8.11	12	0.29	-25	-47	12	3.60	-4.75	-22
Total Operating Income	23	18	20	20	7.38	-18	-38	18	11	1.74	-16
Total Gross Profit	190	175	195	189	185	181	161	173	167	167	170
Total Revenue	203	199	195	201	198	197	180	190	184	184	187
Operating Revenue	203	199	195	201	198	197	180	190	184	184	187
Total Cost of Revenue	13	24	0.00	12	12	15	19	16	17	17	17
Operating Cost of Revenue	13	-	-	12	12	15	19	16	17	17	17
Total Operating Expenses	166	157	175	169	178	200	200	155	156	165	186
Selling, General & Admin Expense	30	24	26	28	41	30	35	30	30	29	50
Marketing Expense	85	94	90	93	90	94	92	77	79	84	86
Research & Development Expense	31	32	30	31	31	32	40	31	33	37	36
Depreciation Expense	21	19	18	17	16	44	33	16	15	16	14
Total Other Income / (Expense), net	-6.71	-6.77	-12	-8.23	-7.09	-6.35	-8.27	-6.24	-7.71	-6.48	-6.56
Interest Expense	11	11	14	15	15	15	15	14	13	12	9.48
Interest & Investment Income	3.93	4.59	4.80	6.33	7.56	8.47	8.65	7.81	7.23	5.45	2.92
Income Tax Expense	5.62	4.67	4.15	4.95	1.30	1.23	-8.11	-47	6.89	-2.77	19
Basic Earnings per Share	$0.03	$0.01	$0.01	$0.02	$0.00	($0.06)	($0.09)	$0.14	($0.01)	($0.01)	($0.10)
Weighted Average Basic Shares Outstanding	379.20M	385.74M	379.67M	376.25M	390.05M	410.32M	413.44M	412.22M	412.43M	412.86M	412.96M
Diluted Earnings per Share	$0.03	$0.01	$0.01	$0.02	$0.00	($0.06)	($0.09)	$0.14	($0.01)	($0.01)	($0.10)
Weighted Average Diluted Shares Outstanding	379.66M	392.17M	388.50M	384.73M	390.05M	410.32M	413.44M	414.34M	412.43M	412.86M	412.96M
Weighted Average Basic & Diluted Shares Outstanding	357.17M	383.61M	381.14M	379.45M	375.21M	395.00M	406.13M	397.85M	396.87M	397.57M	396.19M

This table details how cash moves in and out of GoodRx's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Net Change in Cash & Equivalents	-224	-85	-184	-30	946	-19	17
Net Cash From Operating Activities	184	138	147	179	131	83	45
Net Cash From Continuing Operating Activities	184	138	147	179	131	73	45
Net Income / (Loss) Continuing Operations	16	-8.87	-33	-25	-294	66	44
Consolidated Net Income / (Loss)	16	-8.87	-33	-25	-294	66	44
Depreciation Expense	70	108	54	35	18	14	9.81
Amortization Expense	2.50	3.38	3.41	3.45	3.39	3.38	1.24
Non-Cash Adjustments To Reconcile Net Income	100	124	125	163	444	-1.29	4.62
Changes in Operating Assets and Liabilities, net	-4.87	-87	-2.73	3.46	-41	-8.39	-14
Net Cash From Investing Activities	-70	-56	-210	-179	-92	-37	-3.46
Net Cash From Continuing Investing Activities	-70	-56	-210	-179	-92	-37	-3.46
Purchase of Property, Plant & Equipment	-70	-56	-55	-34	-36	-5.75	-3.46
Acquisitions	0.00	0.00	-157	-140	-56	-31	0.00
Divestitures	0.00	0.00	17	0.00	0.00	-	-
Other Investing Activities, net	0.00	0.00	-15	-4.01	0.00	0.00	-
Net Cash From Financing Activities	-337	-167	-120	-31	906	-55	-25
Net Cash From Continuing Financing Activities	-337	-167	-120	-31	906	-55	-25
Repayment of Debt	-642	-5.27	-7.03	-7.03	-36	-214	-321
Repurchase of Common Equity	-159	-104	-102	0.00	-4.94	0.00	0.00
Issuance of Debt	472	0.00	0.00	-	28	155	902
Issuance of Common Equity	1.77	1.39	0.00	0.00	992	1.62	0.00
Other Financing Activities, net	-11	-60	-11	-23	-73	3.04	3.35
Cash Interest Paid	55	49	31	20	25	48	19
Cash Income Taxes Paid	24	17	4.36	-18	29	19	12

This table details how cash moves in and out of GoodRx's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-147	25	-101	-8.39	-139	-123	33	0.91	3.91	28	-1.75
Net Cash From Operating Activities	9.41	45	87	9.70	43	16	60	30	32	32	34
Net Cash From Continuing Operating Activities	9.41	45	87	9.70	43	16	60	30	32	32	34
Net Income / (Loss) Continuing Operations	11	6.74	3.97	6.69	-1.01	-26	-38	59	-3.29	-1.97	-42
Consolidated Net Income / (Loss)	11	6.74	3.97	6.69	-1.01	-26	-38	59	-3.29	-1.97	-42
Depreciation Expense	21	19	18	17	16	44	33	16	15	16	14
Amortization Expense	0.43	0.42	0.41	0.83	0.84	0.84	0.84	0.85	0.85	0.85	0.85
Non-Cash Adjustments To Reconcile Net Income	25	20	26	28	26	33	43	19	28	32	30
Changes in Operating Assets and Liabilities, net	-48	-1.97	39	-42	0.83	-35	21	-65	-8.42	-14	31
Net Cash From Investing Activities	-52	-17	-16	-17	-21	-13	-14	-15	-14	1.29	-14
Net Cash From Continuing Investing Activities	-52	-17	-16	-17	-21	-13	-14	-15	-14	1.29	-14
Purchase of Property, Plant & Equipment	-22	-17	-16	-17	-21	-13	-14	-15	-14	-15	-14
Acquisitions	-30	-	-	-	-	-	-	-	-	-	-
Net Cash From Financing Activities	-105	-3.53	-172	-0.86	-161	-126	-14	-14	-14	-4.79	-22
Net Cash From Continuing Financing Activities	-105	-3.53	-172	-0.86	-161	-126	-14	-14	-14	-4.79	-22
Repayment of Debt	-1.25	-	-636	-1.76	-3.52	0.00	-1.76	-1.76	-1.76	-1.76	-1.76
Repurchase of Common Equity	-100	-0.19	-5.43	-	-153	-78	-7.71	-8.92	-9.52	-	-18
Other Financing Activities, net	-3.76	-4.25	-2.29	0.04	-4.23	-49	-4.24	-3.97	-2.82	-3.03	-2.00

This table presents GoodRx's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Total Assets	1,388	1,589	1,605	1,608	1,470	387
Total Current Assets	659	873	920	1,089	1,086	87
Cash & Equivalents	448	672	757	941	969	26
Accounts Receivable	146	144	117	118	69	48
Prepaid Expenses	65	57	45	30	46	12
Plant, Property, & Equipment, net	13	16	20	22	23	1.86
Total Noncurrent Assets	716	700	665	497	361	298
Goodwill	411	411	412	330	261	236
Intangible Assets	177	156	190	134	57	26
Noncurrent Deferred & Refundable Income Taxes	77	65	0.00	-	13	2.21
Other Noncurrent Operating Assets	51	68	63	34	30	33
Total Liabilities & Shareholders' Equity	1,388	1,589	1,605	1,608	1,470	387
Total Liabilities	663	827	790	776	759	737
Total Current Liabilities	124	123	76	81	60	33
Short-Term Debt	5.00	8.79	7.03	7.03	7.03	7.03
Accounts Payable	14	36	18	18	10	7.85
Accrued Expenses	99	71	48	51	38	16
Other Current Liabilities	5.64	6.18	4.07	5.85	4.54	2.94
Total Noncurrent Liabilities	540	704	713	695	699	704
Long-Term Debt	487	648	652	656	660	664
Other Noncurrent Operating Liabilities	53	57	62	39	39	40
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	725	762	815	832	711	-1,088
Total Preferred & Common Equity	725	762	815	832	711	-1,088
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	725	762	815	832	711	-1,088
Common Stock	2,166	2,219	2,263	2,247	2,102	9.25
Retained Earnings	-1,441	-1,457	-1,449	-1,416	-1,390	-1,097

This table presents GoodRx's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	1,295	1,355	1,475	1,454	1,708	1,692	1,612	1,567
Total Current Assets	540	627	751	733	969	919	907	878
Cash & Equivalents	301	424	525	533	795	762	761	729
Accounts Receivable	160	131	162	145	121	123	116	121
Prepaid Expenses	79	72	64	55	53	34	29	29
Plant, Property, & Equipment, net	12	14	14	15	17	18	19	22
Total Noncurrent Assets	744	714	710	706	722	755	686	666
Goodwill	422	411	411	411	412	412	412	415
Intangible Assets	199	174	168	162	181	202	197	197
Noncurrent Deferred & Refundable Income Taxes	77	66	65	65	58	63	-	-
Other Noncurrent Operating Assets	46	64	67	68	71	78	76	54
Total Liabilities & Shareholders' Equity	1,295	1,355	1,475	1,454	1,708	1,692	1,612	1,567
Total Liabilities	641	658	806	823	827	797	784	779
Total Current Liabilities	103	114	102	117	118	83	69	85
Short-Term Debt	5.00	3.75	7.03	7.03	7.03	7.03	7.03	7.03
Accounts Payable	15	12	17	34	33	6.80	12	11
Accrued Expenses	78	93	73	71	75	66	48	61
Other Current Liabilities	5.56	5.54	5.39	5.13	3.33	2.73	1.83	6.06
Total Noncurrent Liabilities	538	544	704	706	709	714	715	694
Long-Term Debt	486	488	646	647	649	650	651	653
Other Noncurrent Operating Liabilities	52	56	58	60	60	64	64	40
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	654	696	669	631	881	895	827	788
Total Preferred & Common Equity	654	696	669	631	881	895	827	788
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	654	696	669	631	881	895	827	788
Common Stock	2,084	2,144	2,121	2,089	2,313	2,288	2,279	2,235
Retained Earnings	-1,430	-1,448	-1,452	-1,458	-1,432	-1,393	-1,452	-1,447

This table displays calculated financial ratios and metrics derived from GoodRx's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Growth Metrics	-	-	-	-	-	-	-
Revenue Growth	5.61%	-2.13%	2.83%	35.36%	41.85%	55.59%	0.00%
EBITDA Growth	68.95%	34.90%	15.45%	120.24%	-265.25%	74.05%	0.00%
EBIT Growth	303.73%	-1,884.52%	-87.04%	104.86%	-301.70%	76.98%	0.00%
NOPAT Growth	281.46%	-1,653.91%	-87.04%	104.86%	-273.60%	72.03%	0.00%
Net Income Growth	284.82%	72.99%	-29.99%	91.40%	-487.36%	73.09%	0.00%
EPS Growth	300.00%	75.00%	-33.33%	94.39%	-694.44%	50.00%	0.00%
Operating Cash Flow Growth	32.97%	-5.78%	-17.90%	36.12%	57.70%	84.05%	0.00%
Free Cash Flow Firm Growth	125.60%	69.98%	-17.78%	55.01%	-66.77%	0.00%	0.00%
Invested Capital Growth	2.93%	4.14%	29.46%	36.09%	38.19%	0.00%	0.00%
Revenue Q/Q Growth	0.25%	1.70%	-3.66%	8.71%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	9.33%	5.31%	-7.98%	119.32%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	136.49%	-344.21%	-85.22%	104.50%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	66.81%	-286.81%	-85.22%	104.50%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	201.05%	-159.01%	53.61%	91.10%	0.00%	0.00%	0.00%
EPS Q/Q Growth	233.33%	-166.67%	50.00%	93.94%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	18.63%	-10.38%	-10.89%	24.31%	-1.25%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	1,049.55%	-76.28%	-43.25%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	0.53%	0.54%	-0.41%	-7.49%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-
Gross Margin	93.91%	91.08%	91.51%	93.73%	94.63%	96.39%	97.58%
EBITDA Margin	17.07%	10.67%	7.74%	6.89%	-46.11%	39.58%	35.38%
Operating Margin	8.31%	-3.60%	0.23%	1.80%	-50.07%	35.98%	30.96%
EBIT Margin	7.97%	-4.13%	0.23%	1.80%	-50.07%	35.21%	30.96%
Profit (Net Income) Margin	2.07%	-1.18%	-4.28%	-3.39%	-53.32%	19.53%	17.55%
Tax Burden Percent	52.10%	15.96%	141.31%	248.15%	96.76%	91.35%	83.66%
Interest Burden Percent	49.79%	179.18%	-1,336.65%	-75.91%	110.05%	60.70%	67.77%
Effective Tax Rate	47.90%	0.00%	0.00%	0.00%	0.00%	20.40%	16.34%
Return on Invested Capital (ROIC)	4.53%	-2.59%	0.19%	1.95%	-55.07%	75.55%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-125.48%	-20.17%	18.27%	13.84%	-114.22%	64.58%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-2.33%	1.46%	-4.18%	-5.23%	-107.70%	-118.80%	0.00%
Return on Equity (ROE)	2.21%	-1.12%	-3.99%	-3.27%	-162.77%	-43.24%	0.00%
Cash Return on Invested Capital (CROIC)	1.64%	-6.64%	-25.48%	-28.62%	-87.13%	-124.45%	0.00%
Operating Return on Assets (OROA)	4.25%	-1.94%	0.11%	0.87%	-29.70%	35.34%	0.00%
Return on Assets (ROA)	1.10%	-0.56%	-2.04%	-1.64%	-31.62%	19.60%	0.00%
Return on Common Equity (ROCE)	2.21%	-1.12%	-3.99%	-3.27%	169.75%	-134.16%	0.00%
Return on Equity Simple (ROE_SIMPLE)	2.26%	-1.16%	-4.03%	-3.04%	-41.28%	-6.97%	0.00%
Net Operating Profit after Tax (NOPAT)	34	-19	1.22	9.38	-193	111	65
NOPAT Margin	4.33%	-2.52%	0.16%	1.26%	-35.05%	28.64%	25.90%
Net Nonoperating Expense Percent (NNEP)	130.01%	17.59%	-18.08%	-11.88%	59.15%	10.97%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	2.82%	-1.33%	0.08%	-	-	-	-
Cost of Revenue to Revenue	6.09%	8.92%	8.49%	6.27%	5.37%	3.61%	2.42%
SG&A Expenses to Revenue	14.88%	16.73%	18.89%	20.75%	83.79%	3.78%	3.35%
R&D to Revenue	15.62%	18.11%	18.67%	16.88%	11.23%	7.55%	17.59%
Operating Expenses to Revenue	85.60%	94.68%	91.28%	91.93%	144.69%	60.41%	66.62%
Earnings before Interest and Taxes (EBIT)	63	-31	1.74	13	-276	137	77
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	135	80	59	51	-254	154	88
Valuation Ratios	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.45	3.57	2.27	15.67	22.13	0.00	0.00
Price to Tangible Book Value (P/TBV)	12.94	13.96	8.68	35.40	40.01	0.00	0.00
Price to Revenue (P/Rev)	2.24	3.63	2.41	17.49	28.59	2.94	4.58
Price to Earnings (P/E)	108.13	0.00	0.00	0.00	0.00	17.30	80.30
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.92%	0.00%	0.00%	0.00%	0.00%	5.78%	1.25%
Enterprise Value to Invested Capital (EV/IC)	2.36	3.63	2.44	23.05	37.96	8.58	0.00
Enterprise Value to Revenue (EV/Rev)	2.29	3.61	2.28	17.11	28.04	6.50	0.00
Enterprise Value to EBITDA (EV/EBITDA)	13.43	33.80	29.46	248.24	0.00	16.43	0.00
Enterprise Value to EBIT (EV/EBIT)	28.74	0.00	1,005.70	951.60	0.00	18.46	0.00
Enterprise Value to NOPAT (EV/NOPAT)	52.93	0.00	1,436.71	1,359.43	0.00	22.70	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	9.87	19.56	11.91	71.36	117.55	30.31	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	146.03	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-
Debt to Equity	0.68	0.86	0.81	0.80	0.94	-1.91	0.00
Long-Term Debt to Equity	0.67	0.85	0.80	0.79	0.93	-1.89	0.00
Financial Leverage	0.02	-0.07	-0.23	-0.38	0.94	-1.84	0.00
Leverage Ratio	2.00	2.03	1.95	1.99	5.15	-1.10	0.00
Compound Leverage Factor	1.00	3.63	-26.08	-1.51	5.66	-0.67	0.00
Debt to Total Capital	40.42%	46.28%	44.71%	44.35%	48.39%	209.43%	0.00%
Short-Term Debt to Total Capital	0.41%	0.62%	0.48%	0.47%	0.51%	2.19%	0.00%
Long-Term Debt to Total Capital	40.01%	45.66%	44.23%	43.88%	47.88%	207.24%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	230.06%	0.00%
Common Equity to Total Capital	59.58%	53.72%	55.29%	55.65%	51.61%	-339.50%	0.00%
Debt to EBITDA	3.64	8.20	11.10	12.90	-2.63	4.37	0.00
Net Debt to EBITDA	0.32	-0.20	-1.66	-5.41	1.20	4.20	0.00
Long-Term Debt to EBITDA	3.60	8.09	10.99	12.76	-2.60	4.32	0.00
Debt to NOPAT	14.33	-34.73	541.53	70.64	-3.46	6.03	0.00
Net Debt to NOPAT	1.26	0.84	-80.83	-29.65	1.58	5.80	0.00
Long-Term Debt to NOPAT	14.19	-34.26	535.75	69.89	-3.42	5.97	0.00
Altman Z-Score	1.33	1.66	1.25	10.09	11.72	-0.71	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	204.29%	-210.23%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-
Current Ratio	5.32	7.12	12.05	13.42	18.24	2.59	0.00
Quick Ratio	4.80	6.66	11.46	13.06	17.42	2.22	0.00
Cash Flow Metrics	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	12	-49	-162	-137	-305	-183	0.00
Operating Cash Flow to CapEx	261.41%	247.99%	265.84%	518.85%	366.63%	1,448.70%	1,308.65%
Free Cash Flow to Firm to Interest Expense	0.23	-0.86	-4.73	-5.81	-10.94	-3.36	0.00
Operating Cash Flow to Interest Expense	3.34	2.44	4.29	7.56	4.71	1.53	1.81
Operating Cash Flow Less CapEx to Interest Expense	2.06	1.45	2.67	6.10	3.42	1.42	1.67
Efficiency Ratios	-	-	-	-	-	-	-
Asset Turnover	0.53	0.47	0.48	0.48	0.59	1.00	0.00
Accounts Receivable Turnover	5.47	5.75	6.52	7.98	9.43	8.07	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	55.42	41.97	37.00	33.38	44.20	208.72	0.00
Accounts Payable Turnover	1.91	2.48	3.70	3.36	3.26	1.79	0.00
Days Sales Outstanding (DSO)	66.69	63.43	56.00	45.74	38.73	45.25	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	190.78	147.16	98.71	108.57	111.90	204.45	0.00
Cash Conversion Cycle (CCC)	-124.09	-83.74	-42.71	-62.84	-73.18	-159.20	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-
Invested Capital	768	746	716	553	407	294	0.00
Invested Capital Turnover	1.05	1.03	1.21	1.55	1.57	2.64	0.00
Increase / (Decrease) in Invested Capital	22	30	163	147	112	294	0.00
Enterprise Value (EV)	1,816	2,705	1,748	12,757	15,439	2,524	0.00
Market Capitalization	1,772	2,721	1,846	13,035	15,744	1,142	1,142
Book Value per Share	$1.90	$1.88	$2.06	$2.09	$1.82	($4.80)	$0.00
Tangible Book Value per Share	$0.36	$0.48	$0.54	$0.92	$1.01	($5.96)	$0.00
Total Capital	1,216	1,418	1,474	1,495	1,378	320	0.00
Total Debt	492	656	659	663	667	671	0.00
Total Long-Term Debt	487	648	652	656	660	664	0.00
Net Debt	43	-16	-98	-278	-305	645	0.00
Capital Expenditures (CapEx)	70	56	55	34	36	5.75	3.46
Debt-free, Cash-free Net Working Capital (DFCFNWC)	92	87	93	74	62	34	0.00
Debt-free Net Working Capital (DFNWC)	540	759	850	1,015	1,034	60	0.00
Net Working Capital (NWC)	535	750	843	1,008	1,027	53	0.00
Net Nonoperating Expense (NNE)	18	-10	34	35	101	35	21
Net Nonoperating Obligations (NNO)	43	-16	-98	-278	-305	645	0.00
Total Depreciation and Amortization (D&A)	72	111	58	38	22	17	11
Debt-free, Cash-free Net Working Capital to Revenue	11.61%	11.56%	12.16%	9.88%	11.30%	8.81%	0.00%
Debt-free Net Working Capital to Revenue	68.20%	101.17%	110.94%	136.13%	187.73%	15.52%	0.00%
Net Working Capital to Revenue	67.57%	100.00%	110.02%	135.19%	186.46%	13.71%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.04	($0.02)	($0.08)	($0.06)	($1.07)	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	385.74M	410.32M	412.86M	409.98M	274.70M	0.00	0.00
Adjusted Diluted Earnings per Share	$0.04	($0.02)	($0.08)	($0.06)	($1.07)	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	392.17M	410.32M	412.86M	409.98M	274.70M	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	383.61M	395.00M	397.57M	400.85M	392.13M	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	34	-19	1.22	9.38	-193	111	65
Normalized NOPAT Margin	4.33%	-2.52%	0.16%	1.26%	-35.05%	28.64%	25.90%
Pre Tax Income Margin	3.97%	-7.41%	-3.03%	-1.37%	-55.10%	21.37%	20.98%
Debt Service Ratios	-	-	-	-	-	-	-
EBIT to Interest Expense	1.15	-0.55	0.05	0.57	-9.88	2.51	3.08
NOPAT to Interest Expense	0.62	-0.33	0.04	0.40	-6.91	2.04	2.58
EBIT Less CapEx to Interest Expense	-0.13	-1.53	-1.56	-0.89	-11.16	2.41	2.95
NOPAT Less CapEx to Interest Expense	-0.66	-1.32	-1.58	-1.06	-8.20	1.94	2.44
Payout Ratios	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	3,074.36%
Augmented Payout Ratio	969.16%	-1,172.46%	-309.86%	0.00%	-1.68%	0.00%	3,074.36%

This table displays calculated financial ratios and metrics derived from GoodRx's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	2.57%	0.99%	8.50%	5.76%	7.55%	6.81%	-3.93%	-1.11%	-9.51%	-13.67%	-3.99%
EBITDA Growth	85.11%	44.09%	635.80%	6.86%	-4.44%	44.38%	-632.89%	248.12%	-20.97%	-22.10%	-105.04%
EBIT Growth	216.76%	199.41%	143.79%	8.58%	-22.26%	-1,152.85%	-157.94%	552.38%	-51.95%	-85.22%	-324.50%
NOPAT Growth	160.99%	183.90%	137.18%	-87.19%	-145.79%	-1,152.85%	-143.94%	3,248.10%	-159.36%	101.52%	90.57%
Net Income Growth	1,195.34%	126.05%	110.30%	-88.61%	69.33%	-1,211.82%	7.76%	4,254.49%	-126.76%	95.06%	-130.97%
EPS Growth	0.00%	116.67%	111.11%	-85.71%	100.00%	-500.00%	10.00%	0.00%	-133.33%	88.89%	-150.00%
Operating Cash Flow Growth	-77.90%	181.97%	44.12%	-67.52%	31.89%	-50.22%	78.67%	-41.50%	7.20%	-36.00%	-30.53%
Free Cash Flow Firm Growth	-46.52%	73.79%	75.96%	-90.66%	59.95%	73.76%	62.56%	130.21%	19.73%	28.63%	61.18%
Invested Capital Growth	12.34%	2.93%	2.95%	0.89%	3.77%	4.14%	3.15%	5.60%	20.11%	29.46%	20.26%
Revenue Q/Q Growth	2.21%	1.71%	-2.67%	1.38%	0.63%	9.27%	-5.12%	3.09%	-0.07%	-1.71%	-2.34%
EBITDA Q/Q Growth	18.64%	5.61%	-5.24%	55.91%	-7.66%	492.72%	-118.90%	39.43%	39.52%	2,093.51%	-108.98%
EBIT Q/Q Growth	28.60%	2.44%	-10.72%	169.31%	140.36%	54.88%	-321.38%	92.82%	446.63%	111.05%	-288.26%
NOPAT Q/Q Growth	44.34%	7.67%	-12.70%	144.95%	-98.55%	52.29%	-130.09%	962.40%	-950.50%	111.05%	-288.26%
Net Income Q/Q Growth	63.98%	69.99%	-40.77%	763.43%	96.10%	32.80%	-165.48%	1,886.81%	-66.84%	95.27%	-2,849.40%
EPS Q/Q Growth	200.00%	0.00%	-50.00%	0.00%	100.00%	33.33%	-164.29%	1,500.00%	0.00%	90.00%	0.00%
Operating Cash Flow Q/Q Growth	-78.96%	-48.49%	795.39%	-77.22%	168.38%	-73.67%	101.80%	-7.50%	1.28%	-5.49%	-33.92%
Free Cash Flow Firm Q/Q Growth	-593.74%	6.46%	-369.36%	108.38%	-24.10%	14.20%	-204.70%	135.93%	18.68%	-22.41%	15.53%
Invested Capital Q/Q Growth	9.92%	0.53%	-4.16%	6.08%	0.71%	0.54%	-6.08%	9.11%	1.08%	-0.41%	-3.85%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	93.42%	87.98%	100.00%	94.08%	93.70%	92.29%	89.60%	91.39%	90.93%	90.57%	90.71%
EBITDA Margin	22.03%	18.98%	18.28%	18.78%	12.21%	13.30%	-3.70%	18.58%	13.74%	9.84%	-0.49%
Operating Margin	11.52%	9.15%	10.45%	9.91%	3.73%	-9.30%	-21.30%	9.65%	6.14%	0.94%	-8.39%
EBIT Margin	11.52%	9.15%	9.09%	9.91%	3.73%	-9.30%	-22.52%	9.65%	5.16%	0.94%	-8.39%
Profit (Net Income) Margin	5.45%	3.39%	2.03%	3.34%	-0.51%	-13.16%	-21.39%	30.99%	-1.79%	-1.07%	-22.28%
Tax Burden Percent	66.31%	59.08%	48.88%	57.48%	-344.37%	105.01%	82.61%	487.12%	-91.49%	41.56%	187.39%
Interest Burden Percent	71.29%	62.76%	45.71%	58.59%	3.97%	134.71%	114.98%	65.92%	37.87%	-273.17%	141.74%
Effective Tax Rate	33.69%	40.92%	51.12%	42.52%	444.37%	0.00%	0.00%	-387.12%	191.49%	0.00%	0.00%
Return on Invested Capital (ROIC)	7.63%	5.66%	5.36%	5.56%	-13.30%	-6.68%	-15.05%	45.54%	-6.33%	0.80%	-7.09%
ROIC Less NNEP Spread (ROIC-NNEP)	4.76%	-23.37%	22.15%	-36.37%	271.48%	16.22%	-3.84%	80.30%	-11.25%	2.49%	12.30%
Return on Net Nonoperating Assets (RNNOA)	1.15%	-0.43%	-1.01%	-0.52%	3.19%	-1.17%	0.48%	-8.20%	2.00%	-0.57%	-2.38%
Return on Equity (ROE)	8.78%	5.23%	4.36%	5.04%	-10.11%	-7.85%	-14.57%	37.35%	-4.33%	0.23%	-9.48%
Cash Return on Invested Capital (CROIC)	-5.52%	1.64%	-0.17%	-3.47%	-6.63%	-6.64%	-3.77%	-4.03%	-18.98%	-25.48%	-17.14%
Operating Return on Assets (OROA)	6.68%	4.87%	4.69%	4.85%	1.86%	-4.37%	-10.15%	4.38%	2.45%	0.45%	-4.20%
Return on Assets (ROA)	3.16%	1.81%	1.05%	1.63%	-0.25%	-6.18%	-9.64%	14.06%	-0.85%	-0.51%	-11.14%
Return on Common Equity (ROCE)	8.78%	5.23%	4.36%	5.04%	-10.11%	-7.85%	-14.57%	37.35%	-4.33%	0.23%	-9.48%
Return on Equity Simple (ROE_SIMPLE)	4.35%	0.00%	-2.33%	-8.77%	-1.04%	0.00%	1.71%	1.32%	-5.85%	0.00%	-8.98%
Net Operating Profit after Tax (NOPAT)	16	11	9.97	11	-25	-13	-27	89	-10	1.22	-11
NOPAT Margin	7.64%	5.41%	5.11%	5.70%	-12.85%	-6.51%	-14.91%	47.02%	-5.62%	0.66%	-5.87%
Net Nonoperating Expense Percent (NNEP)	2.87%	29.03%	-16.79%	41.93%	-284.78%	-22.90%	-11.21%	-34.76%	4.92%	-1.69%	-19.39%
Return On Investment Capital (ROIC_SIMPLE)	1.35%	0.88%	-	-	-	-0.90%	-	-	-	0.08%	-
Cost of Revenue to Revenue	6.58%	12.02%	0.00%	5.92%	6.30%	7.71%	10.40%	8.61%	9.07%	9.43%	9.29%
SG&A Expenses to Revenue	14.60%	11.86%	13.12%	13.75%	20.77%	15.44%	19.63%	15.93%	16.10%	15.52%	26.45%
R&D to Revenue	15.34%	15.98%	15.44%	15.38%	15.67%	16.29%	22.01%	16.49%	17.89%	19.97%	19.18%
Operating Expenses to Revenue	81.90%	78.82%	89.55%	84.17%	89.97%	101.59%	110.90%	81.73%	84.78%	89.63%	99.10%
Earnings before Interest and Taxes (EBIT)	23	18	18	20	7.38	-18	-41	18	9.50	1.74	-16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	45	38	36	38	24	26	-6.66	35	25	18	-0.91
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.59	2.45	3.78	4.37	4.44	3.57	2.54	2.45	3.00	2.27	2.36
Price to Tangible Book Value (P/TBV)	50.21	12.94	23.57	32.22	48.19	13.96	7.78	7.79	11.40	8.68	10.57
Price to Revenue (P/Rev)	2.12	2.24	3.33	3.78	3.67	3.63	3.04	2.94	3.33	2.41	2.34
Price to Earnings (P/E)	59.46	108.13	0.00	0.00	0.00	0.00	149.04	185.81	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	1.68%	0.92%	0.00%	0.00%	0.00%	0.00%	0.67%	0.54%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.23	2.36	3.54	3.83	3.89	3.63	2.83	2.64	3.29	2.44	2.49
Enterprise Value to Revenue (EV/Rev)	2.36	2.29	3.42	3.94	3.83	3.61	2.85	2.80	3.19	2.28	2.25
Enterprise Value to EBITDA (EV/EBITDA)	11.88	13.43	21.84	37.56	37.07	33.80	27.64	26.22	43.75	29.46	27.77
Enterprise Value to EBIT (EV/EBIT)	22.99	28.74	101.09	0.00	0.00	0.00	0.00	133.39	0.00	1,005.70	152.28
Enterprise Value to NOPAT (EV/NOPAT)	38.65	52.93	131.34	0.00	0.00	0.00	0.00	190.55	0.00	1,436.71	217.54
Enterprise Value to Operating Cash Flow (EV/OCF)	12.48	9.87	17.42	23.78	19.68	19.56	13.61	16.32	15.99	11.91	10.87
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	146.03	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.75	0.68	0.71	0.98	1.04	0.86	0.74	0.73	0.80	0.81	0.84
Long-Term Debt to Equity	0.74	0.67	0.70	0.96	1.02	0.85	0.74	0.73	0.79	0.80	0.83
Financial Leverage	0.24	0.02	-0.05	0.01	0.01	-0.07	-0.12	-0.10	-0.18	-0.23	-0.19
Leverage Ratio	2.14	2.00	1.94	2.02	2.10	2.03	1.96	1.92	1.95	1.95	1.95
Compound Leverage Factor	1.52	1.26	0.89	1.19	0.08	2.73	2.26	1.26	0.74	-5.33	2.76
Debt to Total Capital	42.86%	40.42%	41.37%	49.37%	50.88%	46.28%	42.66%	42.31%	44.29%	44.71%	45.56%
Short-Term Debt to Total Capital	0.44%	0.41%	0.32%	0.53%	0.55%	0.62%	0.46%	0.45%	0.47%	0.48%	0.49%
Long-Term Debt to Total Capital	42.42%	40.01%	41.05%	48.84%	50.33%	45.66%	42.21%	41.86%	43.82%	44.23%	45.08%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	57.14%	59.58%	58.63%	50.63%	49.12%	53.72%	57.34%	57.69%	55.71%	55.29%	54.44%
Debt to EBITDA	3.10	3.64	3.97	8.03	8.28	8.20	8.63	8.26	12.09	11.10	10.23
Net Debt to EBITDA	1.20	0.32	0.55	1.57	1.53	-0.20	-1.83	-1.32	-1.90	-1.66	-1.07
Long-Term Debt to EBITDA	3.07	3.60	3.94	7.94	8.19	8.09	8.54	8.17	11.96	10.99	10.13
Debt to NOPAT	10.08	14.33	23.89	-31.76	-30.19	-34.73	-134.17	60.01	-139.84	541.53	80.18
Net Debt to NOPAT	3.90	1.26	3.29	-6.22	-5.56	0.84	28.47	-9.61	21.95	-80.83	-8.38
Long-Term Debt to NOPAT	9.98	14.19	23.71	-31.42	-29.87	-34.26	-132.74	59.37	-138.35	535.75	79.32
Altman Z-Score	1.12	1.23	1.98	1.90	1.69	1.69	1.40	1.57	1.75	1.25	1.22
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.23	5.32	5.48	7.32	6.29	7.12	8.23	11.14	13.15	12.05	10.34
Quick Ratio	4.46	4.80	4.85	6.70	5.82	6.66	7.77	10.72	12.72	11.46	10.00
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-77	-11	-12	4.42	-53	-42	-49	47	-132	-162	-132
Operating Cash Flow to CapEx	43.03%	268.82%	547.71%	56.31%	206.58%	123.28%	441.64%	199.65%	225.98%	208.50%	244.88%
Free Cash Flow to Firm to Interest Expense	-7.25	-0.98	-0.82	0.30	-3.60	-2.87	-3.36	3.36	-10.02	-13.57	-13.95
Operating Cash Flow to Interest Expense	0.88	3.94	6.02	0.67	2.91	1.07	4.09	2.13	2.46	2.67	3.56
Operating Cash Flow Less CapEx to Interest Expense	-1.17	2.47	4.92	-0.52	1.50	0.20	3.17	1.06	1.37	1.39	2.11
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.58	0.53	0.52	0.49	0.50	0.47	0.45	0.45	0.47	0.48	0.50
Accounts Receivable Turnover	5.23	5.47	6.27	5.44	5.85	5.75	6.10	6.05	6.23	6.52	7.25
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	59.39	55.42	51.82	47.82	44.81	41.97	37.67	36.52	36.16	37.00	36.07
Accounts Payable Turnover	2.01	1.91	1.74	4.92	2.73	2.48	3.16	5.74	5.51	3.70	4.38
Days Sales Outstanding (DSO)	69.78	66.69	58.18	67.14	62.38	63.43	59.87	60.32	58.55	56.00	50.32
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	181.26	190.78	209.24	74.21	133.63	147.16	115.55	63.59	66.20	98.71	83.29
Cash Conversion Cycle (CCC)	-111.48	-124.09	-151.06	-7.07	-71.24	-83.74	-55.68	-3.27	-7.65	-42.71	-32.97
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	844	768	764	797	751	746	742	790	724	716	719
Invested Capital Turnover	1.00	1.05	1.05	0.98	1.04	1.03	1.01	0.97	1.13	1.21	1.21
Increase / (Decrease) in Invested Capital	93	22	22	7.01	27	30	23	42	121	163	121
Enterprise Value (EV)	1,882	1,816	2,701	3,054	2,925	2,705	2,101	2,086	2,382	1,748	1,790
Market Capitalization	1,692	1,772	2,633	2,927	2,804	2,721	2,240	2,191	2,485	1,846	1,859
Book Value per Share	$1.71	$1.90	$1.84	$1.78	$1.60	$1.88	$2.22	$2.26	$2.08	$2.06	$1.98
Tangible Book Value per Share	$0.09	$0.36	$0.29	$0.24	$0.15	$0.48	$0.72	$0.71	$0.55	$0.54	$0.44
Total Capital	1,145	1,216	1,188	1,322	1,285	1,418	1,537	1,552	1,485	1,474	1,448
Total Debt	491	492	491	653	654	656	656	657	658	659	660
Total Long-Term Debt	486	487	488	646	647	648	649	650	651	652	653
Net Debt	190	43	68	128	120	-16	-139	-105	-103	-98	-69
Capital Expenditures (CapEx)	22	17	16	17	21	13	14	15	14	15	14
Debt-free, Cash-free Net Working Capital (DFCFNWC)	141	92	92	130	90	87	63	82	84	93	72
Debt-free Net Working Capital (DFNWC)	442	540	516	655	623	759	858	844	845	850	800
Net Working Capital (NWC)	437	535	512	648	616	750	851	837	838	843	793
Net Nonoperating Expense (NNE)	4.45	4.00	6.01	4.73	-24	13	12	30	-7.05	3.19	31
Net Nonoperating Obligations (NNO)	190	43	68	128	120	-16	-139	-105	-103	-98	-69
Total Depreciation and Amortization (D&A)	21	20	18	18	17	44	34	17	16	16	15
Debt-free, Cash-free Net Working Capital to Revenue	17.66%	11.61%	11.69%	16.80%	11.78%	11.56%	8.59%	10.97%	11.24%	12.16%	9.01%
Debt-free Net Working Capital to Revenue	55.41%	68.20%	65.31%	84.52%	81.57%	101.17%	116.34%	113.24%	113.10%	110.94%	100.60%
Net Working Capital to Revenue	54.78%	67.57%	64.83%	83.61%	80.65%	100.00%	115.39%	112.30%	112.16%	110.02%	99.71%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.03	$0.01	$0.01	$0.02	$0.00	($0.06)	($0.09)	$0.14	($0.01)	($0.01)	($0.10)
Adjusted Weighted Average Basic Shares Outstanding	379.20M	385.74M	379.67M	376.25M	390.05M	410.32M	413.44M	412.22M	412.43M	412.86M	412.96M
Adjusted Diluted Earnings per Share	$0.03	$0.01	$0.01	$0.02	$0.00	($0.06)	($0.09)	$0.14	($0.01)	($0.01)	($0.10)
Adjusted Weighted Average Diluted Shares Outstanding	379.66M	392.17M	388.50M	384.73M	390.05M	410.32M	413.44M	414.34M	412.43M	412.86M	412.96M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	357.17M	383.61M	381.14M	379.45M	375.21M	395.00M	406.13M	397.85M	396.87M	397.57M	396.19M
Normalized Net Operating Profit after Tax (NOPAT)	16	11	14	11	5.17	-13	-27	13	7.91	1.22	-11
Normalized NOPAT Margin	7.64%	5.41%	7.32%	5.70%	2.61%	-6.51%	-14.91%	6.76%	4.30%	0.66%	-5.87%
Pre Tax Income Margin	8.21%	5.75%	4.15%	5.81%	0.15%	-12.53%	-25.90%	6.36%	1.95%	-2.58%	-11.89%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	2.20	1.60	1.23	1.36	0.50	-1.23	-2.75	1.30	0.72	0.15	-1.66
NOPAT to Interest Expense	1.46	0.95	0.69	0.78	-1.74	-0.86	-1.82	6.35	-0.79	0.10	-1.16
EBIT Less CapEx to Interest Expense	0.14	0.14	0.13	0.18	-0.90	-2.10	-3.68	0.24	-0.37	-1.14	-3.11
NOPAT Less CapEx to Interest Expense	-0.60	-0.52	-0.41	-0.40	-3.14	-1.73	-2.75	5.28	-1.88	-1.18	-2.61
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	370.87%	969.16%	-1,458.06%	-406.90%	-3,760.18%	-1,172.46%	173.99%	308.68%	-56.75%	-309.86%	-143.73%

Frequently Asked Questions About GoodRx's Financials

When does GoodRx's fiscal year end?

According to the most recent income statement we have on file, GoodRx's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has GoodRx's net income changed over the last 6 years?

GoodRx's net income were at $16.39 million at the end of 2024, a 284.8% decrease from 2023, and a 62.6% decrease since 2018. See GoodRx's forecast for analyst expectations on what’s next for the company.

What is GoodRx's operating income?

GoodRx's total operating income in 2024 was $65.85 million, based on the following breakdown:

Total Gross Profit: $744.11 million
Total Operating Expenses: $678.26 million

How has GoodRx revenue changed over the last 6 years?

Over the last 6 years, GoodRx's total revenue changed from $249.52 million in 2018 to $792.32 million in 2024, a change of 217.5%.

How much debt does GoodRx have?

GoodRx's total liabilities were at $663.41 million at the end of 2024, a 19.8% decrease from 2023, and a 10.0% decrease since 2019.

How much cash does GoodRx have?

In the past 5 years, GoodRx's cash and equivalents has ranged from $26.05 million in 2019 to $968.69 million in 2020, and is currently $448.35 million as of their latest financial filing in 2024.

How has GoodRx's book value per share changed over the last 6 years?

Over the last 6 years, GoodRx's book value per share changed from 0.00 in 2018 to 1.90 in 2024, a change of 190.1%.

Related Companies

This page (NASDAQ:GDRX) was last updated on 5/24/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GoodRx (GDRX) Financials

Frequently Asked Questions About GoodRx's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GoodRx (GDRX) Financials

Annual Income Statements for GoodRx

Quarterly Income Statements for GoodRx

Annual Cash Flow Statements for GoodRx

Quarterly Cash Flow Statements for GoodRx

Annual Balance Sheets for GoodRx

Quarterly Balance Sheets for GoodRx

Annual Metrics And Ratios for GoodRx

Quarterly Metrics And Ratios for GoodRx

Frequently Asked Questions About GoodRx's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools